(±)-trans-ACPD

Pricing Availability   Qty
Cat.No. 0187 - trans-ACPD | C7H11NO4 | CAS No. 67684-64-4
Description: Group I and II mGlu agonist
Chemical Name: (±)-1-Aminocyclopentane-trans-1,3-dicarboxylic acid
Purity: ≥99% (HPLC)
Datasheet
Citations (7)
Reviews (1)
Literature (10)

Biological Activity

Equimolecular mixture of (1S,3R)- and (1R,3S)-ACPD. Selective agonist for metabotropic glutamate receptors; active at both group I and group II mGlu receptors (EC50 values are 2, 15, 23 and ~800 μM at mGluR2, mGluR1, mGluR5 and mGluR4 respectively).

(1S,3R)-ACPD and cis-ACPD also available.

Technical Data

M. Wt 173.17
Formula C7H11NO4
Storage Store at RT
Purity ≥99% (HPLC)
CAS Number 67684-64-4
PubChem ID 23789032
InChI Key DXLSPTHQGVGVTN-NAAZMWONSA-N
Smiles [H][C@@]1(CC[C@@](N)(C1)C(O)=O)C(O)=O.[H][C@]1(CC[C@](N)(C1)C(O)=O)C(O)=O

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
water 5 with gentle warming
1eq. NaOH 8.66 50

Preparing Stock Solutions

The following data is based on the product molecular weight 173.17. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
0.5 mM 11.55 mL 57.75 mL 115.49 mL
2.5 mM 2.31 mL 11.55 mL 23.1 mL
5 mM 1.15 mL 5.77 mL 11.55 mL
25 mM 0.23 mL 1.15 mL 2.31 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

Product Datasheets

Certificate of Analysis / Product Datasheet
Select another batch:

References

References are publications that support the biological activity of the product.

Conti et al (2002) Synthesis and pharmacology of 3-hydroxy-Δ2-isoxazoline-cyclopentance analogues of glutamic acid Farmaco 57 889 PMID: 12484537

Knopfel et al (1995) Metabotropic glutamate receptors: novel targets for drug development. J.Med.Chem. 38 1417 PMID: 7738999

Nakanishi (1992) Molecular diversity of glutamate receptors and implications for brain functions. Science 258 597 PMID: 1329206

Pin and Duvoisin (1995) The metabotropic glutamate receptors: structure and functions. Neuropharmacology 34 1 PMID: 7623957


If you know of a relevant reference for (±)-trans-ACPD, please let us know.

View Related Products by Product Action

View all Glutamate (Metabotropic) Group I Receptor Agonists

Keywords: trans-ACPD, trans-ACPD supplier, Group, II, group, I, mGlur, agonists, Receptors, mGlu2, mGlu3, mGluR2, mGluR3, Glutamate, Metabotropic, mGlu1, mGlu5, mGluR1, mGluR5, tacpd, trans-acpd, (Metabotropic), 0187, Tocris Bioscience

7 Citations for (±)-trans-ACPD

Citations are publications that use Tocris products. Selected citations for (±)-trans-ACPD include:

Fujino and Oertel (2003) Bidirectional synaptic plasticity in the cerebellum-like mammalian dorsal cochlear nucleus. Proc Natl Acad Sci U S A 100 265 PMID: 12486245

Nishi et al (2003) Metabotropic mGlu5 receptors regulate adenosine A2A receptor signaling. Proc Natl Acad Sci U S A 100 1322 PMID: 12538871

Young and Sun (2007) Long-term modifications in the strength of excitatory associative inputs in the piriform cortex. Chem Senses 32 783 PMID: 17634388

Rojas et al (2013) Activation of group I metabotropic glutamate receptors potentiates heteromeric kainate receptors. Mol Pharmacol 83 106 PMID: 23066089


Do you know of a great paper that uses (±)-trans-ACPD from Tocris? Please let us know.

Reviews for (±)-trans-ACPD

Average Rating: 5 (Based on 1 Review.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%

Have you used (±)-trans-ACPD?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:


An mGluR agonist.
By Anonymous on 02/21/2018
Assay Type: Ex Vivo
Species: Rat

trans-ACPD is mGluR agonist (Group I and II). We used at 100 microM in rat brain slices. It increases intracellular Ca2+ in astrocytes.


Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


GPCR

GPCR Product Listing

A collection of over 450 products for G protein-coupled receptors, the listing includes research tools for the study of:

  • Rhodopsin-like Receptors
  • Glutamate Receptors
  • Frizzled Receptors
  • GPCR Signaling
Pain

Pain Research Product Guide

A collection of over 280 products for pain research, the guide includes research tools for the study of:

  • Nociception
  • Ion Channels
  • G-Protein-Coupled Receptors
  • Intracellular Signaling
Metabotropic Glutamate Receptors

Metabotropic Glutamate Receptors Scientific Review

Written by Francine Acher, this review discusses the pharmacology and therapeutic potential of mGlu receptors, and the compounds acting upon them; compounds available from Tocris are listed.

Addiction

Addiction Poster

The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.

Depression

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.

Epilepsy

Epilepsy Poster

Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.

Huntington's Disease

Huntington's Disease Poster

Huntington's disease (HD) is a monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the MSN intracellular signaling pathways implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.

Learning & Memory

Learning & Memory Poster

Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.

Pain

Pain Poster

Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.

Parkinson's

Parkinson's Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.